They’re Back – Will We See the M&A Boon? Hatteras White Paper on Biotech M&A
By: Clay Thorp, General Partner, Hatteras Venture Partners Michael Yee of Jefferies is one of the best analysts in biotech, and he knows his… Read More
By: Clay Thorp, General Partner, Hatteras Venture Partners Michael Yee of Jefferies is one of the best analysts in biotech, and he knows his… Read More
With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current… Read More
Company also secures $9.5 million in Series A funding to expand its resources to meet rapidly growing customer demand PALO ALTO, Calif.–(BUSINESS… Read More
Acquisition Enables Company to Provide More High-Value, Patient-Centered Services Through Its Network of More Than 1,000 Independent Primary Care Practices and Health Centers Bethesda, Md. Read More
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia… Read More
A new biotech startup with operations in Seattle and Durham, N.C., has launched with $40 million in new funding and a leadership team peppered with… Read More
Proceeds Used to Acquire ClinEdge and Invest Further in Technology & Data Platform SAN FRANCISCO–(BUSINESS WIRE)– Morgan Stanley Expansion Capital and Ally Bridge Group,… Read More
First Indication for Lead TREM2 Agonist Program Announced as Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Financing Led by Vida Ventures; Stefan… Read More
MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally… Read More
Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke MIAMI, June 23, 2021 (GLOBE NEWSWIRE) — RapidPulse,… Read More